Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salsalate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salsalate SCHEMBL4090721 | 0.95 | HSD17B10 (0.70) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| Salsalate SCHEMBL18889812 | 0.95 | HSD17B10 (0.70) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| Salsalate SCHEMBL3879224 | 0.89 | KDM4E (0.82) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| Salsalate SCHEMBL6422927 | 0.89 | KDM4E (0.82) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| Salicylic Acid SCHEMBL2638195 | 0.83 | KDM4E (0.61) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| SCHEMBL26736432 | 0.83 | HSD17B10 (0.72) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| SCHEMBL3635482 | 0.82 | HPGD (0.76) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| Salicylic Acid SCHEMBL9981 | 0.82 | KDM4E (0.91) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| Salicylic Acid SCHEMBL29801565 | 0.82 | KDM4E (0.91) | HSD17B10HPGDALDH1A1KDM4EALOX15 | |
| Salicylic Acid SCHEMBL28120274 | 0.82 | KDM4E (0.91) | HSD17B10HPGDALDH1A1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496881-A4 | CHROMIUM COMPOSITIONS AND METHODS FOR USING THE SAME FOR INHIBITING DRUG-INDUCED INSULIN RESISTANCE | NUTRITION 21 INC (US) | 2007-04-04 | — | — | EP | claimed |
| US-20050214384-A1 | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance | N21 ACQUISITION HOLDING, LLC | 2005-09-29 | — | — | US | claimed |
| EP-1496881-A2 | CHROMIUM COMPOSITIONS AND METHODS FOR USING THE SAME FOR INHIBITING DRUG-INDUCED INSULIN RESISTANCE | Nutrition 21, Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003090671-A2 | CHROMIUM COMPOSITIONS AND METHODS FOR USING THE SAME FOR INHIBITING DRUG-INDUCED INSULIN RESISTANCE | NUTRITION 21, INC. (US) | 2003-11-06 | — | — | WO | claimed |
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| EP-3829536-A1 | PHARMACEUTICAL FORMULATION AND SYSTEM AND METHOD FOR DELIVERY | Rilento Pharma LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-111729161-A | Methods and devices for compound delivery | 方特慕控股第一私人有限公司 | 2020-10-02 | — | — | CN | disclosed |
| EP-3698832-A1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | Fontem Holdings 1 B.V. (NL) | 2020-08-26 | — | — | EP | disclosed |
| US-20200225244-A1 | COMPOSITIONS AND METHODS FOR ASSESSING PAINFUL DEMYELINATING AND NONDEMYELINATING DISEASES | Sanford Burnham Prebys Medical Discovery Institute | 2020-07-16 | — | — | US | disclosed |
| EP-3096636-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2020-04-15 | — | — | EP | disclosed |
| US-20200069595-A1 | PHARMACEUTICAL FORMULATION AND SYSTEM AND METHOD FOR DELIVERY | RILENTO PHARMA, LLC | 2020-03-05 | — | — | US | disclosed |
| WO-2020047277-A1 | PHARMACEUTICAL FORMULATION AND SYSTEM AND METHOD FOR DELIVERY | RILENTO PHARMA, LLC (US) | 2020-03-05 | — | — | WO | disclosed |
| CN-204147375-U | Be designed for the aerosol generation equipment producing condensation aerosol | NICOTINE TECHNOLOGY INC E | 2015-02-11 | — | — | CN | disclosed |
| US-20140190496-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014085719-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-7629302-B2 | Lubricating oil additive and lubricating oil composition | NIPPON OIL CORPORATION (JP) | 2009-12-08 | — | — | US | disclosed |
| CN-100347277-C | Lubricating oil additive and lubricating oil composition | NIPPON OIL CORP (JP) | 2007-11-07 | — | — | CN | disclosed |
| US-20060063686-A1 | Lubricating oil additive and lubricating oil composition | NIPPON OIL CORPORATION (JP) | 2006-03-23 | — | — | US | disclosed |
| CN-1714140-A | Lubricating oil additive and lubricating oil composition | NIPPON OIL CORP (JP) | 2005-12-28 | — | — | CN | disclosed |
| EP-1580257-A1 | LUBRICATING OIL ADDITIVE AND LUBRICATING OIL COMPOSITION | Nippon Oil Corporation (JP) | 2005-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200225244-A1 | COMPOSITIONS AND METHODS FOR ASSESSING PAINFUL DEMYELINATING AND NONDEMYELINATING DISEASES | KCNAB1, CACNA1D, SCN1A | HSD17B10 2534/4885HPGD 927/4885ALDH1A1 3704/4885 |
| US-20050214384-A1 | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance | GPR119, IRS1, CTRB1 | HSD17B10 218/4885HPGD 3231/4885ALDH1A1 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.